

Organized by



The Mediterranean League
Against Thromboembolic Diseases

Abstracts & Early registration
by 28th February 2010

Preliminary Programme

Congress **21st International**
on Thrombosis

A new era in antithrombotics

www.thrombosis2010.org

Information, programmes
and updates are provided
only by e-mail newsletters

SIGN IN our mailing list!

July **06 09 2010**
Milan, Italy



The Mediterranean League
Against Thromboembolic Diseases

Committees

Chairman

Pier Mannuccio **Mannucci**

Executive Committee

Rosanna **Asselta**

Marco **Cattaneo**

Raimondo **de Cristofaro**

Valerio **De Stefano**

Stefano **Duga**

Augusto B. **Federici**

Massimo **Franchini**

Ida **Martinelli**

Marco **Moia**

Flora **Peyvandi**

Armando **Tripodi**

International Committee

David **Bergqvist** • Henri **Bounameaux** • Benjamin **Brenner** •

Harry **Buller** • Sergio **Coccheri** • Ola **Dahl** • Bengt **Eriksson** •

Argiro **Gialeraki** • Sylvia **Haas** • Job **Harenberg** • Ajay K. **Kakkar** •

Vijay K. **Kakkar** • Irene **Kontopoulou-Griva** • Marcel **Levi** •

Gordon D.O. **Low** • Michael **Makris** • Jasone **Monasterio Aspiri** •

Manuel **Monreal** • William **Ouweland** • Leon **Poller** •

Frits R. **Rosendaal** • Meyer **Samama** • Graham A. **Turpie** •

Vicente **Vicente**

Advisory Committee

Rosanna **Abbate** • Walter **Agno** • Giancarlo **Agnelli** •

Tiziano **Barbui** • Francesco **Bernardi** • Chiara **Cerletti** •

Nicola **Ciavarella** • Michele **Cortellaro** • Benilde **Cosmi** •

Armando **D'Angelo** • Giovanni **Davi** • Giovanni **de Gaetano** •

Giovanni **Di Minno** • Anna **Falanga** • Guido **Finazzi** •

Monica **Galli** • Gian Franco **Gensini** • Elvira **Grandone** •

Paolo **Gresele** • Lucia **Iacoviello** • Davide **Imberti** •

Domenico **Inzitari** • Ido **Iori** • Alfonso **Iorio** • Raffaele **Landolfi** •

Maddalena **Lettino** • Giuseppe **Licata** • Roberto **Lorenzet** •

Maurizio **Margaglione** • Guglielmo **Mariani** •

Francesco **Marongiu** • Piera Angelica **Merlini** • Gualtiero **Palareti** •

Carlo **Patrono** • Vittorio **Pengo** • Franco **Piovella** •

Paolo **Prandoni** • Domenico **Prisco** • Giuseppe **Remuzzi** •

Paolo **Simioni** • Sergio **Siragusa** • Danilo **Toni** • Alberto **Tosetto** •

Elena **Tremoli** • Marco **Tubaro** • Francesco **Violi**

Mediterranean League Council Members

President

Christos **Liapis**, *Greece*

Past President

David **Varon**, *Israel*

General Secretary

Maria Teresa **Santos**, *Spain*

Country Councilors

Cherif **Abdelkhirane**, *Morocco* • Nejat **Akar**, *Turkey* •

Abdulkareem M. **Al Momen**, *Saudi Arabia* • Lina **Badimon**, *Spain* •

Ana **Bronic**, *Croatia* • Manuel **Campos**, *Portugal* •

Jacqueline **Conard**, *France* • Luis Manuel **Cunha-Ribeiro**, *Spain* •

Maria Benedetta **Donati**, *Italy* • Ismail **Elalamy**, *France* •

Ivo **Elezovic**, *Serbia* • Amparo **Estelles**, *Spain* •

Sami **Guermazi**, *Tunisia* • Antonios **Hatzizacharias**, *Greece* •

Nevine **Kassim**, *Egypt* • Athanassios **Nicolaides**, *Cyprus* •

Paolo **Prandoni**, *Italy* • Maria Teresa **Santos**, *Spain* •

Uri **Seligsohn**, *Israel* • Mojca **Stegnar**, *Slovenia* •

Ali **Taher**, *Lebanon* • Zoubida **Tazi**, *Morocco* •

Iovcho B. **Topalov**, *Bulgaria* • Anthi **Travlou**, *Greece* •

Urgut **Ulutin**, *Turkey* • David **Varon**, *Israel*

Submit your Abstract on-line

at www.thrombosis2010.org

by 28th February 2010

Selected abstracts will be presented either as oral communications or posters.

All accepted abstracts will be published in a supplement to "Pathophysiology of Haemostasis and Thrombosis".

Register on-line

at www.thrombosis2010.org

Early bird rate by 28 February 2010

Regular rate after 28 February 2010

Late Registration rate after 30 June 2010;

Student and MLTD members reduced registration fees

Congress Venue: **Marriott Hotel**, Via Washington 66, Milan, Italy

Exhibition dates: 6-9 July 2010

Official language: English

CME: European and Italian CME accreditation will be available.

Congress registration includes:

- Admission to the congress and the exhibition
- Congress kit (Programme, Book of Abstracts, Badge and Congress bag)
- Congress documentation (Attendance certificate, CME certificate for Italian and European delegates)
- Daily lunch and tea/coffee
- Opening ceremony and welcome reception

Accommodation deadline: 6 May 2010

Social events:

Welcome Ceremony at Marriot Hotel, 6 July 2010;

Delegates Dinner at the Leonardo da Vinci Science and Technology Museum & Cloisters;

Opera nights at "La Scala" available upon early booking;

Accompanying persons' programme can be booked on-line in the "Accommodation" page.

Keep Updated: Don't miss the chance to be updated!

If you wish to receive news regarding this Congress, sign up on the web site for email updates! Programme changes will be only sent electronically to those who signed up for it.

Scientific Secretariat:

c/o **Prof Mannucci**

Via Pace 9

20122 Milan, Italy

Phone: +39 02 58102846 and +39 02 50320724

Fax: +39 02 50320723

secretariat@thrombosis2010.org

Organizing Secretariat:

ArsEducandi Srl

Viale Gian Galeazzo

20136 Milan, Italy

Phone: +39 02 58189528

Fax: +39 02 8373386

E-mail: registration.thrombosis2010@arseducandi.it

Sponsor special lane: +39 02 58189517

Thrombosis2010@arseducandi.it



14:00 - 19:00 **Registration**

Satellite Symposium

15:00 -16:30 **Baxter • Thrombotic microangiopathies.**
 The genetic basis of congenital thrombotic thrombocytopenic purpura (TTP). **F. Peyvandi**, *Italy*
 New therapies in acquired TTP. **M. Scully**, *UK*
 New diagnostic and prognostic aspects of acquired TTP. **J. Kremer-Hovinga**, *Switzerland*
 Rethinking thrombotic microangiopathies. **G. Remuzzi**, *Italy*

Opening Symposium

17:00 - 18:30 **Air pollution and thrombosis.**
 Air pollution, blood clotting, and cardiovascular disease: evidence from epidemiological studies and impact on the population. **A. Peters**, *Germany*
 Beyond the DNA sequence: epigenetic mechanisms of prothrombotic air pollution effects. **A. Baccarelli**, *Italy*
 Inhaled particles and thrombosis: a toxicology perspective from air pollution to nanoparticles. **N.L. Mills**, *UK*

18:30 - 19:00 **Plenary lecture: M.Samama**, *France*. Title TBA

19:30 - 20:00 **Opening Ceremony**

Morning sessions

8:00 - 8:30 Haemotransfusion in coronary heart disease: friend or foe? **M. Lettino**, *Italy*
 Hypercoagulability and thrombosis in sickle cell anemia and thalassemia. **D. Varon**, *Israel*
 Leukocytosis as a thrombosis risk factor. **T. Barbui**, *Italy*
 8:30 - 9:00 New antiplatelet agents: why they are badly needed by the cardiologist. **P. A. Merlini**, *Italy*
 Familial thrombophilia without a positive laboratory screening. **J. Conard**, *France*
 Metabolic modulation of inflammation-driven coagulation. **E. Stroes**, *the Netherlands*

9:30 - 10:00 **Oral Communications**

Debate and Lectures

11:30 - 12:30 Is it clinically useful to extend to the calf the ultrasound examination of deep leg veins? **S.M. Schellong**, *Germany* (Yes) vs **G. Palareti**, *Italy* (No)
 Role of statins and exercise on vulnerable plaques. **C. Liapis**, *Greece*
 Thrombosis in neonates and children. **U. Nowack-Goettl**, *Germany*

Satellite Symposia

13:00 - 14:30 **Bayer • TBA**
 13:00 - 14:30 **Octapharma • Joint CLAHT and MLTD symposium**
 Antiphospholipid syndrome. **R. Forastiero**, *Argentina*
 Thrombotic complications in the treatment of patients with bleeding disorders. **M. Mijares**, *Argentina*
 TBA
 TBA

15:00 - 16:30 **Sanofi Aventis • Advantages and limitations of biosimilar low molecular weight heparins.**
 How are biosimilar LMWHs currently used and what is the expected future? **A. J. Kakkar**, *UK*
 Recommendations for preparation of biosimilar LMWHs according to the SSC on anticoagulation of the ISTH compared to FDA and EMEA views. **J. Harenberg**, *Germany*
 Biostatistical requirements for development of biosimilar LMWHs. **P. Mismetti**, *France*

15:00 - 16:30 **Instrumentation Lab • Heparin induced thrombocytopenia (HIT) diagnosis and treatment.**
 HIT: pathophysiology, incidence and guidelines. **A. Greinacher**, *Germany*
 Laboratory aspects in HIT diagnosis: current status. **I. Elalamy**, *France*
 Clinical aspects and challenges in patient management. **G. Palareti**, *Italy*

15:00 - 16:30 **Glaxo Smith Kline • TBA**

Symposia

17:00 - 18:00 **Venous thromboembolism in special clinical conditions: natural history.**
 VTE and estrogen therapy (oral contraceptive and hormone-replacement). **B. Brenner**, *Israel*
 VTE in the very elderly. **A. Leizorovicz**, *France*
 VTE in the very young. **M. Monreal**, *Spain*

17:00 - 18:30 **Advances in peripheral arterial disease.**
 Peripheral arterial disease in the spectrum of atherothrombosis. **G. D.O. Lowe**, *UK*
 Asymptomatic peripheral arterial disease: impact on clinical practice. **F. Violi**, *Italy*
 Antiplatelet treatment. **G. Y. Lip**, *UK*

17:00 - 18:30 **Genomewide association studies.**
 Stroke. **M. Breteler**, *the Netherlands*
 Venous thromboembolism. **P. Morange**, *France*
 Coronary artery disease. **S. Kathiresan**, *USA*

Faculty Dinner



Morning sessions

- 8:00 - 8:30 Biomarkers for the diagnosis of venous thromboembolism. **A. Perrier**, *Switzerland*
Moderate hyperhomocysteinemia: marker or cause of a disease? **R. Abbate**, *Italy*
Antiplatelet therapy in diabetes. **S. Coccheri**, *Italy*
- 8:30 - 9:00 Cerebral vein thrombosis. **J. Ferro**, *Portugal*
Which antithrombotic and antiplatelet therapies in the ambulance for acute coronary syndrome? **M. Tubaro**, *Italy*
Pharmacoepidemiology of gastrointestinal bleeding complications of antiplatelet agents. **A. Lanas**, *Spain*

9:30 - 10:00 Oral Communications

Debate and Lectures

- 11:30 - 12:30 Variable antiplatelet response to thienopyridines: should we use lab tests?
J. Collet, *France* (Yes) vs **B. Rocca**, *Italy* (No)
Adjunctive anti thrombotic agents to amplify thrombolysis in ischemic stroke.
J. Grotta, *USA*
Discovery of quantitative trait loci involved in platelet function.
W. Ouwehand, *UK*

Satellite Symposia

- 13:00 - 14:30 **Boehringer Ingelheim** • TBA
Schering Plough • TBA

- 15:00 - 16:30 **Astra Zeneca lecture**
Optimizing antiplatelet therapy: insight from large outcome trials. **D. Ardissino**, *Italy*
Rovi • TBA

Symposia

- 17:00 - 18:30 **New anticoagulants: highlights on methodological issues.**
Lack of standards between antithrombotic trials in orthopedics: the scenario.
O.E. Dahl, *Norway*
Methodological issues in trials assessing primary prophylaxis of venous thromboembolism. **M. Samama**, *France*
Make clinical studies in medical patients closer to usual hospital care.
J. Harenberg, *Germany*
Guidelines on clinical testing of new antithrombotics in surgical populations.
A. K. Kakkar, *UK*
- 17:00 - 18:30 **Therapeutic advances in stroke.**
Thrombolysis in acute stroke: present evidences and future perspectives.
D. Toni, *Italy*
Secondary prevention of cerebral ischemia of arterial origin. **A. Algra**, *the Netherlands*
Secondary prevention of cardioembolic stroke: old and new drugs. **J. Ferro**, *Portugal*
- 17:00 - 18:30 **Platelets and inflammation.**
Platelets and atherosclerosis. **M. Gawaz**, *Germany*
Platelets and allergic disorders. **P. Gresele**, *Italy*
Platelets, inflammation and acute coronary syndrome. **L. Badimon**, *Spain*

La Scala • Romeo & Juliet

Morning sessions

- 8:00 - 8:30 Thromboprophylaxis in "minor" orthopedic surgery. **H. Bounameaux**, *Switzerland*
Antithrombotic agents after vascular surgery. **D. Bergqvist**, *Sweden*
A renaissance of the contact phase of blood coagulation. **U. Seligsohn**, *Israel*
- 8:30 - 9:00 News on the anticoagulant pathway of blood coagulation. **J. Corral**, *Spain*
Highlights of the International Conference on Thrombosis and Hemostasis Issues in Cancer (ICTHIC) 2010. **A. Falanga**, *Italy*
What is new on the clinical aspects of fibrinolysis and thrombolysis.
J.A Paramo, *Spain*

9:30 - 10:00 Oral Communications

Debate and Lectures

- 11:30 - 12:30 Thromboembolic pulmonary hypertension: watchful waiting vs. early surgery.
F. Piovello, *Italy* vs **A.M. D'Armini**, *Italy*
The future of anticoagulant therapy. **G. Agnelli**, *Italy*
The role of tissue factor in coronary artery disease. **T.F Luscher**, *Switzerland*

Symposia

- 13:00 - 14:30 **Venous and arterial thromboembolism: an overlapping risk.**
Clinical VTE and subsequent risk of arterial thrombotic events in non-provoked populations. **G.D.O. Lowe**, *UK*
Surgical triggering of venous and arterial thromboembolism: Immediate and long-term consequences. **O. E. Dahl**, *Norway*
Pregnancy and obstetric complications and the link to venous and arterial thrombosis. **I. Greer**, *UK*
- 13:00 - 14:30 **Special problems and strategies in anticoagulation.**
Bridging strategies for interruption of anticoagulation for invasive procedures.
S. Schulman, *Canada*
Antisense anticoagulant treatment. **M. Levi**, *the Netherlands*
Anticoagulant and thrombolytic treatment of portal vein and digestive tract thrombosis. **F. Leebeek**, *the Netherlands*
- 13:00 - 14:30 **Atrial fibrillation and heart failure as thrombotic disorders.**
Atrial fibrillation as a thrombotic disease. **G. Y Lip**, *UK*
Heart failure and thrombotic complications. **C. Torp-Pedersen**, *Denmark*
Heart failure as a hypercoagulable state. **PW Kamphuisen**, *the Netherlands*
- 15:00 - 16:30 **The benefits and risks of low-dose aspirin in primary prevention of atherothrombosis.**
Should aspirin be used for the primary prevention of vascular disease?
C. Baigent, *UK*
Aspirin for people with diabetes: current evidence and ongoing trials.
J. Armitage, *UK*
Ongoing trials on aspirin for primary prevention: will they deliver? **G. Tognoni**, *Italy*
- 15:00 - 16:30 **Long-term complications of venous thromboembolism.**
The optimal duration of anticoagulant therapy in patients with venous thromboembolism. **P. Prandoni**, *Italy*
The post-thrombotic syndrome: prevalence, prognostication and need for progress. **S. Kahn**, *Canada*
Chronic thromboembolic pulmonary hypertension. **I. Lang**, *Austria*
- 15:00 - 16:30 **Dietary habits and cardiovascular risk.**
Is the evidence from observational studies sufficient to state that Mediterranean diet reduces CV risk? **A. Kafatos**, *Greece*
Wine, beer and spirit are really horses of a different colour? **L. Iacoviello**, *Italy*
Food and health: is inflammation the round-about? **M.I. Covas**, *Spain*

La Scala • Barbieri di Siviglia

